$1.43
-0.06 (-4.03%)
Open$1.46
Previous Close$1.49
Day High$1.52
Day Low$1.40
52W High$19.03
52W Low$0.97
Volume—
Avg Volume361.7K
Market Cap7.59M
P/E Ratio—
EPS$-6.03
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+455.9% upside
Current
$1.43
$1.43
Target
$7.95
$7.95
$5.82
$7.95 avg
$9.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 913.8K | 821.5K | 988.8K |
| Net Income | -134,164 | -149,522 | -162,197 |
| Profit Margin | -14.7% | -18.2% | -16.4% |
| EBITDA | -201,888 | -178,889 | -216,043 |
| Free Cash Flow | -124,461 | -98,758 | -111,181 |
| Rev Growth | +16.4% | +11.0% | +21.1% |
| Debt/Equity | 1.08 | 0.86 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |